You just read:

FDA Files Supplemental New Drug Application for Boehringer Ingelheim's Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 06, 2015, 08:00 ET